Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NKGen Biotech ( (NKGN) ) has provided an announcement.
On April 28, 2026, NKGen Biotech and its subsidiary NKGen Operating Biotech amended their secured convertible loan agreement with AlpineBrook Capital, securing an additional $607,200 convertible loan that yields $552,000 in net proceeds and carries a conversion price of $0.08 per share. As part of the deal, NKGen increased the consideration shares to 12,009,780, issued a new secured convertible note and a 10-year warrant with a 9.99% ownership cap and anti-dilution protections, and entered into a voting agreement with key shareholders to support an increase in authorized common shares to accommodate potential conversions and warrant exercises, all executed as unregistered offerings under Securities Act exemptions.
The additional financing and equity-linked incentives deepen AlpineBrook’s economic exposure while potentially increasing future dilution for existing shareholders. The voting agreement and required shareholder approval for a larger share pool underscore NKGen’s reliance on equity-capital structures to support its funding needs and may influence its capital structure and control dynamics as subsequent financings close.
More about NKGen Biotech
NKGen Biotech, Inc. is a Delaware-based biotechnology company focused on developing therapies using its proprietary natural killer (NK) cell technologies. The company operates through its wholly owned subsidiary NKGen Operating Biotech, Inc. and targets capital-raising arrangements that often involve convertible debt and equity-linked securities to fund its operations and growth in the biotech sector.
Average Trading Volume: 5,100
Technical Sentiment Signal: Sell
Current Market Cap: $7.84M
Learn more about NKGN stock on TipRanks’ Stock Analysis page.